- /
- Supported exchanges
- / US
- / DMAC.NASDAQ
DiaMedica Therapeutics Inc (DMAC NASDAQ) stock market data APIs
DiaMedica Therapeutics Inc Financial Data Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with DiaMedica Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get DiaMedica Therapeutics Inc data using free add-ons & libraries
Get DiaMedica Therapeutics Inc Fundamental Data
DiaMedica Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -34 354 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.175
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DiaMedica Therapeutics Inc News
New
DiaMedica Therapeutics Enters Oversold Territory (DMAC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a te...
After-Hours Earnings Report for March 30, 2026 : PRGS, PHR, DMAC, AIRJ, SPCE, HQI, SGMO, RNXT, INLX, FTHM
The following companies are expected to report earnings after hours on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Progress Software Corporation (PRGS)is...
Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight
DelveInsight Business Research LLP The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pi...
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
This article first appeared on GuruFocus. Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Warning! GuruFocus has detected 5 Warning Signs with RKT. Is RKT fairly val...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.